143 related articles for article (PubMed ID: 23205568)
21. The Effect of Plan Type and Comprehensive Medication Reviews on High-Risk Medication Use.
Almodovar AS; Axon DR; Coleman AM; Warholak T; Nahata MC
J Manag Care Spec Pharm; 2018 May; 24(5):416-422. PubMed ID: 29694292
[TBL] [Abstract][Full Text] [Related]
22. Does good medication adherence really save payers money?
Stuart BC; Dai M; Xu J; Loh FH; S Dougherty J
Med Care; 2015 Jun; 53(6):517-23. PubMed ID: 25961659
[TBL] [Abstract][Full Text] [Related]
23. Out-of-plan medication in Medicare Part D.
Roberto PN; Stuart B
Am J Manag Care; 2014 Sep; 20(9):743-8. PubMed ID: 25365749
[TBL] [Abstract][Full Text] [Related]
24. Guideline-recommended medications: variation across Medicare Advantage plans and associated mortality.
Selim AJ; Fincke BG; Rogers WH; Qian S; Selim BJ; Kazis LE
J Manag Care Pharm; 2013 Mar; 19(2):132-8. PubMed ID: 23461429
[TBL] [Abstract][Full Text] [Related]
25. The effects of coding intensity in Medicare Advantage on plan benefits and finances.
Jacobs PD; Kronick R
Health Serv Res; 2021 Apr; 56(2):178-187. PubMed ID: 33165932
[TBL] [Abstract][Full Text] [Related]
26. Attribute substitution in early enrollment decisions into Medicare prescription drug plans.
Frakt AB; Pizer SD
Health Econ; 2008 Apr; 17(4):513-21. PubMed ID: 17935198
[TBL] [Abstract][Full Text] [Related]
27. Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison.
Gellad WF; Donohue JM; Zhao X; Mor MK; Thorpe CT; Smith J; Good CB; Fine MJ; Morden NE
Ann Intern Med; 2013 Jul; 159(2):105-14. PubMed ID: 23752663
[TBL] [Abstract][Full Text] [Related]
28. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
Davis MM; Patel MS; Halasyamani LK
J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
[TBL] [Abstract][Full Text] [Related]
29. Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes.
Fung V; Mangione CM; Huang J; Turk N; Quiter ES; Schmittdiel JA; Hsu J
Health Serv Res; 2010 Apr; 45(2):355-75. PubMed ID: 20050931
[TBL] [Abstract][Full Text] [Related]
30. Variability of COPD inhaler coverage in Medicare Part D.
Wormser B; Socal MP; Anderson G
Am J Manag Care; 2021 May; 27(5):187-193. PubMed ID: 34002960
[TBL] [Abstract][Full Text] [Related]
31. The effect of Medicare Part D on drug and medical spending.
Zhang Y; Donohue JM; Lave JR; O'Donnell G; Newhouse JP
N Engl J Med; 2009 Jul; 361(1):52-61. PubMed ID: 19571283
[TBL] [Abstract][Full Text] [Related]
32. Psychometric evaluation of the Medicare Advantage and prescription drug plan disenrollment reasons survey.
Martino SC; Elliott MN; Zaslavsky AM; Orr N; Bogart A; Ye F; Damberg CL
Health Serv Res; 2019 Aug; 54(4):930-939. PubMed ID: 31025723
[TBL] [Abstract][Full Text] [Related]
33. Impact of medication synchronization programs on proportion of days covered (PDC) scores and Medicare Part D medication-related adherence metrics.
Bernard K; Cowles B; McCall K; Henningsen RM; O'Toole M; Tu C
J Am Pharm Assoc (2003); 2019; 59(3):343-348. PubMed ID: 30940515
[TBL] [Abstract][Full Text] [Related]
34. Cost minimization of medicare part D prescription drug plan expenditures.
Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR
Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958
[TBL] [Abstract][Full Text] [Related]
35. Medication oversupply in patients with diabetes.
Thorpe CT; Johnson H; Dopp AL; Thorpe JM; Ronk K; Everett CM; Palta M; Mott DA; Chewning B; Schleiden L; Smith MA
Res Social Adm Pharm; 2015; 11(3):382-400. PubMed ID: 25288448
[TBL] [Abstract][Full Text] [Related]
36. Antiparkinson drug use and adherence in medicare part D beneficiaries with Parkinson's disease.
Wei YJ; Palumbo FB; Simoni-Wastila L; Shulman LM; Stuart B; Beardsley R; Brown C
Clin Ther; 2013 Oct; 35(10):1513-1525.e1. PubMed ID: 24139423
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
[TBL] [Abstract][Full Text] [Related]
38. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
Socal MP; Ezebilo I; Bai G; Anderson GF
Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
[TBL] [Abstract][Full Text] [Related]
39. Association of Changes in Medication Use and Adherence With Accountable Care Organization Exposure in Patients With Cardiovascular Disease or Diabetes.
McWilliams JM; Najafzadeh M; Shrank WH; Polinski JM
JAMA Cardiol; 2017 Sep; 2(9):1019-1023. PubMed ID: 28700790
[TBL] [Abstract][Full Text] [Related]
40. Use of diabetes medications in traditional Medicare and Medicare Advantage.
Landon BE; Zaslavsky AM; Souza J; Ayanian JZ
Am J Manag Care; 2021 Mar; 27(3):e80-e88. PubMed ID: 33720673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
